- Immutep Limited IMMP introduced new information in 1st line non-small cell lung most cancers from the INSIGHT-003 Phase I trial evaluating eftilagimod alpha at the side of customary-of-care anti-PD-1 remedy and doublet chemotherapy (carboplatin/pemetrexed).
- The triple mixture remedy stays properly-tolerated and continues to indicate favorable preliminary efficacy alerts, attaining a 67% total response charge (ORR) and 91% illness management charge (DCR) in superior or metastatic non-squamous 1st line non-small cell lung most cancers sufferers (N=21).
- Related: Immutep Shares Spike As Cancer Treatment Shows Favorable Results In Phase 2 Trial.
- The 67% ORR no matter PD-L1 expression, and 65% response charge in sufferers with PD-L1 TPS <50% for the triple mixture examine favorably to reported outcomes from a registrational trial of anti-PD-1 and doublet chemotherapy in the identical affected person inhabitants that yielded an ORR of 48% no matter PD-L1 expression and a response charge of 40.8% in sufferers with PD-L1 TPS <50%.
- The INSIGHT-003 trial was not too long ago expanded to enroll 50 sufferers based mostly on the favorable security and efficacy outcomes, and extra information is anticipated to be introduced at a serious medical convention in H2 CY2023.
- Price Action: IMMP shares are up 10.8% at $2.5489 on the final verify Wednesday.
© 2023 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
